Legal Representation
Attorney
Laurence Rickles
USPTO Deadlines
Next Deadline
124 days remaining
Statement of Use Due - Extension 3 Granted
Due Date
December 19, 2025
Extension Available
Until December 19, 2024
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 2, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 2, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 2, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Dec 3, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 3, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 3, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Dec 3, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jun 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 4, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jun 4, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 4, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 19, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 24, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 24, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 4, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 20, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 18, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 16, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 9, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 14, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders
Classification
International Classes
005